NCT03432520View on ClinicalTrials.gov

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Active, not recruitingOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2032

Conditions
Hemophilia A
Interventions
GENETIC

SPK-8011

Observational long-term safety follow-up study of participants previously treated with SPK-8011 in any Spark-sponsored SPK-8011 study

GENETIC

SPK-8016

Observational long-term safety follow-up study of participants previously treated with SPK-8016 in any Spark-sponsored SPK-8016 study

Trial Locations (12)

2050

Royal Prince Alfred Hospital Department of Cell & Molecular Therapies, Sydney

10733

Pennsylvania State University Milton S. Hershey Medical Center, Hershey

15213

Hemophilia Center of Western Pennsylvania, Pittsburgh

19104

The Children's Hospital of Philadelphia, Philadelphia

19107

Thomas Jefferson University, Philadelphia

23298

Virginia Commonwealth University, Richmond

39110

Mississippi Center for Advanced Medicine, Madison

64108

Truman Medical Centers, Kansas City

97239

Oregon Health & Science University, Portland

02115

Boston Children's Hospital, Boston

Unknown

The Alfred Hospital & Monash Medical Centre, Melbourne

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
lead

Spark Therapeutics, Inc.

INDUSTRY

NCT03432520 - Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A | Biotech Hunter | Biotech Hunter